Table 2.
Clinical features obtained from the medical records (MR) from the Lady Ridgeway Hospital (LRH) and the telephone survey (TS)
| No. | Clinical features obtained from MR at LRH | ||
|---|---|---|---|
| Variable | Frequency | ||
| 1. | Family history of RB | ||
| Total sample ( N = 171; 100%) | |||
| Yes | 005 (02.9%) | ||
| No | 166 (97.1%) | ||
| Unilateral ( N = 120; 70.2%) | |||
| Yes | 001 (00.8%) | ||
| No | 119 (99.2%) | ||
| Bilateral ( N = 51; 29.8%) | |||
| Yes | 04 (07.8%) | ||
| No | 47 (92.2%) | ||
| 2. | Age (months) of RB patients when symptom/sign was first observed ( N = 90; 100%) | ||
| 00–06 | 23 (25.5%) | ||
| 07–12 | 24 (26.7%) | ||
| 13–18 | 15 (16.7%) | ||
| 19–24 | 07 (07.8%) | ||
| 25–30 | 07 (07.8%) | ||
| 31–36 | 02 (02.2%) | ||
| ≥ 37 | 12 (13.3%) | ||
| 3. | Symptoms/signs at first presentation ( N = 171; 100%) | ||
| Leukocoria | 98 (57.3%) | ||
| Strabismus | 28 (16.4%) | ||
| Leukocoria and strabismus | 25 (14.6%) | ||
| Others* | 08 (04.8%) | ||
| Missing data | 12 (07.0%) | ||
| 4. | Duration (weeks) between first observing symptom/sign & first attendance at tertiary care unit ( N = 90; 100%) | ||
| ≤ 01 | 31 (34.4%) | ||
| > 01–04 | 07 (07.8%) | ||
| 05–08 | 20 (22.2%) | ||
| 09–12 | 04 (04.4%) | ||
| ≥ 13 | 28 (31.1%) | ||
| 5. | Clinical staging of disease | ||
| a. | Total group ( N = 171; 100%) | ||
| Group A | 002 (01.2%) | ||
| Group B | 015 (08.8%) | ||
| Group C | 003 (01.7%) | ||
| Group D | 044 (25.7%) | ||
| Group E | 107 (62.6%) | ||
| b. | Unilateral ( N = 120; 70.2%) | ||
| Group A | 02 (01.7%) | ||
| Group B | 11 (09.2%) | ||
| Group C | 03 (02.5%) | ||
| Group D | 35 (29.2%) | ||
| Group E | 69 (57.5%) | ||
| c. | Bilateral ( N = 51; 29.8%) | ||
| i. | First eye | ||
| Group A | 00 (00.0%) | ||
| Group B | 04 (07.8%) | ||
| Group C | 00 (00.0%) | ||
| Group D | 09 (17.6%) | ||
| Group E | 38 (74.5%) | ||
| ii. | Second eye | ||
| Group A | 12 (23.5%) | ||
| Group B | 11 (21.6%) | ||
| Group C | 01 (02.0%) | ||
| Group D | 27 (52.9%) | ||
| Group E | 00 (00.0%) | ||
| 6. | Parental consanguinity ( N = 171) | ||
| Yes | 020 (11.7%) | ||
| No | 151 (88.3%) | ||
| 7. | Undergone enucleation | ||
| a. | Total sample (171; 100%) | ||
| Yes | 121 (70.8%) | ||
| No | 050 (29.2%) | ||
| b. | Unilateral ( N = 120) | ||
| Yes | 83 (69.2%) | ||
| No | 37 (30.8%) | ||
| c. | Bilateral ( N = 51) | ||
| Yes | 38 (74.5%) | ||
| No | 13 (25.5%) | ||
| 8. | Modalities of RB therapy ( N = 171; 100%) | ||
| Primary enucleation | 46 (26.9%) | ||
| Secondary enucleation | 75 (43.9%) | ||
| Ocular salvage therapy | 50 (29.2%) | ||
| 9. | Mortality ( N = 171; 100%) | ||
| Yes | 002 (01.2%) | ||
| No | 168 (98.2%) | ||
*Others (Symptoms at first referral) include visual inattention, upper lid lump, red eye, hazy cornea, total retinal detachment, glaucoma, uveitis, proptosis, large eye ball, white reflex and hyphema)